{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:27:22Z","timestamp":1791419242300,"version":"4.3.3"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Eumycetoma is a chronic subcutaneous neglected tropical disease that can be caused by more than 40 different fungal causative agents. The most common causative agents produce black grains and belong to the fungal orders Sordariales and Pleosporales. The current antifungal agents used to treat eumycetoma are itraconazole or terbinafine, however, their cure rates are low. To find novel drugs for eumycetoma, we screened 400 diverse drug-like molecules from the Pandemic Response Box against common eumycetoma causative agents as part of the Open Source Mycetoma initiative (MycetOS). 26 compounds were able to inhibit the growth of <jats:italic>Madurella mycetomatis<\/jats:italic>, <jats:italic>Madurella pseudomycetomatis<\/jats:italic> and <jats:italic>Madurella tropicana<\/jats:italic>, 26 compounds inhibited <jats:italic>Falciformispora senegalensis<\/jats:italic> and seven inhibited growth of <jats:italic>Medicopsis romeroi in vitro<\/jats:italic>. Four compounds were able to inhibit the growth of all five species of fungi tested. They are the benzimidazole carbamates fenbendazole and carbendazim, the 8-aminoquinolone derivative tafenoquine and MMV1578570. Minimal inhibitory concentrations were then determined for the compounds active against <jats:italic>M<\/jats:italic>. <jats:italic>mycetomatis<\/jats:italic>. Compounds showing potent activity <jats:italic>in vitro<\/jats:italic> were further tested <jats:italic>in vivo<\/jats:italic>. Fenbendazole, MMV1782387, ravuconazole and olorofim were able to significantly prolong <jats:italic>Galleria mellonella<\/jats:italic> larvae survival and are promising candidates to explore in mycetoma treatment and to also serve as scaffolds for medicinal chemistry optimisation in the search for novel antifungals to treat eumycetoma.<\/jats:p>","DOI":"10.1371\/journal.pntd.0010159","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T18:36:01Z","timestamp":1643999761000},"page":"e0010159","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-3825","authenticated-orcid":true,"given":"Wilson","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-6149","authenticated-orcid":true,"given":"Bertrand","family":"Nyuykonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-4304","authenticated-orcid":true,"given":"Mickey","family":"Konings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8553-8640","authenticated-orcid":true,"given":"Juli","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Fahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-3317","authenticated-orcid":true,"given":"Alexandro","family":"Bonifaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-4751","authenticated-orcid":true,"given":"Matthew","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-4213","authenticated-orcid":true,"given":"Benjamin","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-9580","authenticated-orcid":true,"given":"Kirandeep","family":"Samby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-6068","authenticated-orcid":true,"given":"Jeremy","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-8783","authenticated-orcid":true,"given":"Wendy","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"issue":"1","key":"pntd.0010159.ref001","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1473-3099(15)00359-X","article-title":"Mycetoma: a unique neglected tropical disease","volume":"16","author":"EE Zijlstra","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"key":"pntd.0010159.ref002","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/9781555817381.ch125","article-title":"Fungi Causing Eumycotic Mycetoma. M","author":"AOA Ahmed","year":"2015","journal-title":"anual of Clinical Microbiology"},{"issue":"11","key":"pntd.0010159.ref003","doi-asserted-by":"crossref","first-page":"e2550","DOI":"10.1371\/journal.pntd.0002550","article-title":"Global burden of human mycetoma: a systematic review and meta-analysis.","volume":"7","author":"WW van de Sande","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0010159.ref004","doi-asserted-by":"crossref","first-page":"e3218","DOI":"10.1371\/journal.pntd.0003218","article-title":"Mycetoma Medical Therapy.","volume":"8","author":"O Welsh","year":"2014","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"4","key":"pntd.0010159.ref005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clindermatol.2011.06.027","article-title":"Actinomycetoma and advances in its treatment","volume":"30","author":"O Welsh","year":"2012","journal-title":"Clin Dermatol"},{"issue":"8","key":"pntd.0010159.ref006","doi-asserted-by":"crossref","first-page":"e0008307","DOI":"10.1371\/journal.pntd.0008307","article-title":"Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects","volume":"14","author":"LYM Elkheir","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0010159.ref007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.trstmh.2012.07.003","article-title":"Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan","volume":"106","author":"HA Zein","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"pntd.0010159.ref008","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.trstmh.2010.11.008","article-title":"The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis","volume":"105","author":"AH Fahal","year":"2011","journal-title":"Transactions of The Royal Society of Tropical Medicine and Hygiene"},{"issue":"4","key":"pntd.0010159.ref009","doi-asserted-by":"crossref","first-page":"e0231871","DOI":"10.1371\/journal.pone.0231871","article-title":"Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018","volume":"15","author":"D Sow","year":"2020","journal-title":"PLoS One."},{"issue":"4","key":"pntd.0010159.ref010","doi-asserted-by":"crossref","first-page":"e0006437","DOI":"10.1371\/journal.pntd.0006437","article-title":"Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma","volume":"12","author":"W Lim","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0010159.ref011","doi-asserted-by":"crossref","first-page":"e02373","DOI":"10.1128\/AAC.02373-18","article-title":"Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Fasciola hepatica Activity","volume":"63","author":"C Machicado","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"pntd.0010159.ref012","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13071-019-3747-6","article-title":"center screening of the Pathogen Box collection for schistosomiasis drug discovery.","volume":"12","author":"M Maccesi","year":"2019","journal-title":"Multi-Parasites & Vectors."},{"issue":"9","key":"pntd.0010159.ref013","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1128\/JCM.43.9.4349-4356.2005","article-title":"Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size","volume":"43","author":"WW van de Sande","year":"2005","journal-title":"Journal of clinical microbiology"},{"key":"pntd.0010159.ref014","article-title":"A Short Tandem Repeat Assay for Studying Genetic Variation in Madurella mycetomatis (MmySTR)","author":"B Nyuykonge","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"4","key":"pntd.0010159.ref015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/AAC.49.4.1364-1368.2005","article-title":"Testing of the In Vitro Susceptibilities of Madurella mycetomatis to Six Antifungal Agents by Using the Sensititre System in Comparison with a Viability-Based 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5- [(Phenylamino)Carbonyl]-2-Tetrazolium Hydroxide (XTT) Assay and a Modified NCCLS Method.","volume":"49","author":"WWJ van de Sande","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"pntd.0010159.ref016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/mmy\/myu098","article-title":"In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals","volume":"53","author":"SA Ahmed","year":"2015","journal-title":"Med Mycol"},{"key":"pntd.0010159.ref017","article-title":"Development and validation of an in vitro resazurin-based susceptibility assay against Madurella mycetomatis","author":"SO Abd Algaffar","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"pntd.0010159.ref018","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/mmy\/myx064","article-title":"Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis","volume":"56","author":"W Kloezen","year":"2018","journal-title":"Medical Mycology"},{"issue":"6","key":"pntd.0010159.ref019","doi-asserted-by":"crossref","first-page":"e2942","DOI":"10.1371\/journal.pntd.0002942","article-title":"Madurella mycetomatis is highly susceptible to ravuconazole","volume":"8","author":"SA Ahmed","year":"2014","journal-title":"PLoS neglected tropical diseases"},{"issue":"11","key":"pntd.0010159.ref020","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1128\/AAC.01170-12","article-title":"In vitro antifungal activity of isavuconazole against Madurella mycetomatis","volume":"56","author":"W Kloezen","year":"2012","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"4","key":"pntd.0010159.ref021","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dkz529","article-title":"Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim","volume":"75","author":"W Lim","year":"2020","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"7","key":"pntd.0010159.ref022","doi-asserted-by":"crossref","first-page":"e0003926","DOI":"10.1371\/journal.pntd.0003926","article-title":"A Madurella mycetomatis Grain Model in Galleria mellonella Larvae","volume":"9","author":"W Kloezen","year":"2015","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"4","key":"pntd.0010159.ref023","doi-asserted-by":"crossref","first-page":"e0008190","DOI":"10.1371\/journal.pntd.0008190","article-title":"Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae","volume":"14","author":"G Sheehan","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0010159.ref024","doi-asserted-by":"crossref","first-page":"e0009488","DOI":"10.1371\/journal.pntd.0009488","article-title":"The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma","volume":"15","author":"M Konings","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0010159.ref025","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1073\/pnas.0813394106","article-title":"Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease","volume":"106","author":"LE Cowen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0010159.ref026","article-title":"In vitro susceptibility testing for black grain eumycetoma causative agents","author":"WWJ van de Sande","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0010159.ref027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/B978-0-7020-6896-6.00029-6","volume-title":"Clinical Immunology","author":"AK Lord","year":"2019","edition":"5"},{"issue":"10","key":"pntd.0010159.ref028","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1128\/AAC.44.10.2883-2886.2000","article-title":"In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans","volume":"44","author":"T Yamazumi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"pntd.0010159.ref029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00643-20","article-title":"Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi","volume":"64","author":"H Zheng","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pntd.0010159.ref030","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1128\/AAC.49.12.5136-5138.2005","article-title":"In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi","volume":"49","author":"M Cuenca-Estrella","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pntd.0010159.ref031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13693780500088416","article-title":"In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi","volume":"43","author":"GM Gonz\u00e1lez","year":"2005","journal-title":"Med Mycol"},{"issue":"8","key":"pntd.0010159.ref032","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.48.8.3107-3111.2004","article-title":"In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates","volume":"48","author":"M Cuenca-Estrella","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pntd.0010159.ref033","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/AAC.47.10.3161-3164.2003","article-title":"In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization","volume":"47","author":"C Serena","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pntd.0010159.ref034","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi","volume":"41","author":"DJ Diekema","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"2","key":"pntd.0010159.ref035","first-page":"79","article-title":"[Drug properties of fosravuconazole L-lysine ethanolate (NAILIN","volume":"153","author":"M Nakano","year":"2019","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"pntd.0010159.ref036","unstructured":"initiative DfND. Study the efficacy of fosravuconazole as a potential new, safe, and affordable treatment for patients with eumycetoma 2015. Available from: https:\/\/dndi.org\/research-development\/portfolio\/fosravuconazole\/."},{"issue":"4","key":"pntd.0010159.ref037","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.3314\/mmj.16-00006","article-title":"Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis","volume":"57","author":"H. Yamaguchi","year":"2016","journal-title":"Medical Mycology Journal"},{"key":"pntd.0010159.ref038","unstructured":"initiative DfND. Evaluate new therapeutic regimens of benznidazole as monotherapy, or in combination with fosravuconazole, for the treatment of adult patients with chronic Chagas disease. 2013. Available from: https:\/\/dndi.org\/research-development\/portfolio\/new-benz-regimens\/."},{"issue":"2","key":"pntd.0010159.ref039","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12281-010-0018-6","article-title":"Use of Antifungal Combination Therapy: Agents, Order, and Timing.","volume":"4","author":"MD Johnson","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"issue":"11","key":"pntd.0010159.ref040","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependent fungicidal activities of azoles","volume":"42","author":"EK Manavathu","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0010159.ref041","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1038\/s41467-018-05497-7","article-title":"Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus","volume":"9","author":"B Gei\u00dfel","year":"2018","journal-title":"Nat Commun"},{"key":"pntd.0010159.ref042","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-1-4939-0694-9_29","volume-title":"Handbook of Antimicrobial Resistance","author":"M Zavrel","year":"2017"},{"key":"pntd.0010159.ref043","doi-asserted-by":"crossref","first-page":"myac003","DOI":"10.1093\/mmy\/myac003","article-title":"Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella","volume":"22","author":"W Lim","year":"2022","journal-title":"Med Mycol"},{"issue":"45","key":"pntd.0010159.ref044","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"JD Oliver","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"pntd.0010159.ref045","doi-asserted-by":"crossref","first-page":"e00231","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus","volume":"62","author":"S du Pr\u00e9","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"pntd.0010159.ref046","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/187152610791163336","article-title":"Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy","volume":"10","author":"MA Phillips","year":"2010","journal-title":"Infect Disord Drug Targets"},{"issue":"3","key":"pntd.0010159.ref047","article-title":"Review of the Novel Investigational Antifungal Olorofim","volume":"6","author":"NP Wiederhold","year":"2020","journal-title":"J Fungi (Basel)."},{"issue":"1","key":"pntd.0010159.ref048","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0027-5107(74)80066-7","article-title":"On the genetic activity of benzimidazole and thiophanate fungicides on diploid Aspergillus nidulans","volume":"26","author":"A Kappas","year":"1974","journal-title":"Mutat Res"},{"issue":"4","key":"pntd.0010159.ref049","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0169-4758(90)90227-U","article-title":"Mode of action of benzimidazoles","volume":"6","author":"E. Lacey","year":"1990","journal-title":"Parasitology Today"},{"issue":"1","key":"pntd.0010159.ref050","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1038\/s41598-018-30158-6","article-title":"Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways","volume":"8","author":"N Dogra","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"pntd.0010159.ref051","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1094\/PHYTO-08-15-0186-R","article-title":"Mechanism of Action of the Benzimidazole Fungicide on Fusarium graminearum: Interfering with Polymerization of Monomeric Tubulin But Not Polymerized Microtubule","volume":"106","author":"Y Zhou","year":"2016","journal-title":"Phytopathology"},{"issue":"1","key":"pntd.0010159.ref052","first-page":"49","article-title":"A literature review of the anthelmintic, fenbendazole","volume":"24","author":"TF Booze","year":"1982","journal-title":"Vet Hum Toxicol"},{"key":"pntd.0010159.ref053","first-page":"64","article-title":"Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model","author":"HC de Oliveira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0010159.ref054","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1871520616666161221113623","article-title":"Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties.","volume":"18","author":"K Goyal","year":"2018","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"pntd.0010159.ref055","first-page":"355","article-title":"Fenbendazole as a potential anticancer drug","volume":"33","author":"Q Duan","year":"2013","journal-title":"Anticancer Res"},{"key":"pntd.0010159.ref056","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpddr.2019.09.001","article-title":"Similarities and differences in the biotransformation and transcriptomic responses of Caenorhabditis elegans and Haemonchus contortus to five different benzimidazole drugs","volume":"11","author":"SJ Stasiuk","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T18:36:48Z","timestamp":1643999808000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010159"}},"subtitle":[],"editor":[{"given":"Husain","family":"Poonawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010159","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}